Sohag University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Sohag Egypt (2006)

Organization Overview

First Clinical Trial
2012
NCT01600612
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Associate professor, dept. of Obstetrics & gynecology, Sohag University, Egypt | Bahaa Mohammed Refaie | Department of obstetrics and Gynecology, Sohag university, Egypt | Department of Obstetrics and Gynecology, Sohag university, Egypt | Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University | Faculty of medicine sohag university | Faculty of Medicine, Sohag University | Faculty of Medicine, Sohag University, Egypt. | Lecturer of anesthesia and ICU sohag university | Lecturer of ENT sohag university | Pediatrics Department, Faculty of Medicine, Sohag University | Sohag Faculty of medicine | Sohag Faculty of Medicine | Sohag Faculty of Medicine, Sohag university | Sohag Faculty of Medicine, Sohag University | Sohag University

Active Ingredients

Drugs in Phase 4 Trials (20)

bupivacaine (Exparel) (7 trials)

dexamethasone (1 trial)

ethanol (1 trial)

hyaluronic acid (1 trial)

hydroxypropyl cellulose (1 trial)

insulin human (humulin) (1 trial)

insulin lispro (humalog) (1 trial)

lidocaine (xylocaine) (4 trials)

minoxidil (loniten) (1 trial)

ombitasvir (Viekira Pak) (2 trials)

paritaprevir (viekira pak) (2 trials)

polyethylene glycol (1 trial)

propylene glycol (2 trials)

recombinant human choriogonadotropin alfa (Ovidrel) (1 trial)

ribavirin (virazole) (2 trials)

ritonavir (Norvir) (2 trials)

tacrolimus (prograf) (2 trials)

tetryzoline (1 trial)

tocopherol (1 trial)

triamcinolone (kenalog) (3 trials)

Drugs in Phase 3 Trials (10)

cobalamin (1 trial)

dapoxetine (priligy) (2 trials)

folic acid (1 trial)

hyaluronidase (human recombinant) (hylenex) (1 trial)

latanoprost (xalatan) (1 trial)

multivitamins (1 trial)

platelet rich plasma (1 trial)

progesterone (progestasert) (1 trial)

tadalafil (cialis) (1 trial)

terbinafine (lamisil) (1 trial)

Drugs in Phase 2 Trials (7)

hydrocortisone (solu-cortef) (1 trial)

levetiracetam (keppra) (1 trial)

magnesium sulfate (Tis-U-Sol) (2 trials)

midazolam (versed) (1 trial)

myoinositol (1 trial)

sildenafil (viagra) (1 trial)

vitamin c (1 trial)

Drugs in Phase 1 Trials (3)

doxorubicin (Doxil) (1 trial)

ketamine (ketalar) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Other Trials (18)

atropine (1 trial)

bleomycin (blenoxane) (1 trial)

carbetocin (1 trial)

copper (cu-7) (1 trial)

daclatasvir (daklinza) (1 trial)

dexmedetomidine (precedex) (1 trial)

epinephrine (levophed) (1 trial)

fluorouracil (efudex) (1 trial)

ketorolac (acuvail) (1 trial)

misoprostol (cytotec) (1 trial)

nalbuphine (nubain) (1 trial)

ondansetron (zofran) (1 trial)

oxytocin (syntocinon) (1 trial)

procyanidin (2 trials)

selenium (1 trial)

silver nanoparticles (1 trial)

simeprevir (olysio) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Alopecia (Phase 4)

Alopecia Areata (Phase 4)

Arthritis (Phase 4)

Arthritis, Juvenile (Phase 4)

Coinfection (Phase 4)

Hypertension (Phase 2)

Hypertension, Pulmonary (Phase 2)

Infertility (Phase 4)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Persistent Fetal Circulation Syndrome (Phase 2)

Premature Birth (Phase 3)

Premature Ejaculation (Phase 3)

Spondylarthritis (Phase 4)

Vitiligo (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 58